← All trials
NCT05308979
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Apr 4, 2022
- Last posted
- May 23, 2022
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, IrvineLead sponsor
- Kaiser PermanenteCollaborator
- University of California, IrvineOverall official - principal investigator
- University of California, IrvineReponsible party - principal investigator
- University of California, IrvineStudy chair
- University of California, IrvineStudy director
- St. Joseph Hospital of OrangeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.